Rs. 13.00 per
30 s per pack
The following serious adverse reactions are described below: Acute Interstitial Nephritis, Cyanocobalamin (Vitamin B-12) Deficiency, Clostridium difficile Associated Diarrhea, Bone Fracture, Hypomagnesemia
It should not be used in patients with In patients with known hypersensitivity to any component of the formulation, Hypersensitivity reactions, including anaphylaxis.
Acute Interstitial Nephritis: Acute interstitial nephritis is observed in patients taking PPIs including lansoprazole. Acute interstitial nephritis may occur at any point during PPI therapy and is generally attributed to an idiopathic hypersensitivity reaction. Discontinue Remit if acute interstitial nephritis develops.
Cyanocobalamin (Vitamin B-12) Deficiency: Daily treatment with any acid-suppressing medications over a long period of time (e.g., longer than 3 years) may lead to malabsorption of cyanocobalamin (Vitamin B-12) caused by hypo- or achlorhydria.
This Medicine should not be use in Pregnancy.
Atazanavir: Do not co-administer with REMIT DR because atazanavir systemic concentrations may be substantially decreased. Drugs with pH-dependent absorption (e.g., ampicillin esters, digoxin, iron salts, ketoconazole, erlotinib, mycophenolate mofetil): REMIT DR may interfere with absorption of drugs for which gastric pH is important for bioavailability.
Warfarin: Patients taking concomitant warfarin may require monitoring for increases in international normalized ratio (INR) and prothrombin time.
Tacrolimus: Concomitant tacrolimus use may increase tacrolimus whole blood concentrations. Methotrexate: REMIT DR may increase serum levels of methotrexate.